COVID-19 Presenting As Miller Fisher Syndrome in a Patient With a History of Guillain-Barré Syndrome: A Case Report

Louay Aldabain 1, Metri Haddaden 2, Rehan Farooqi 1, Malaz Alissa 1

1. Hospital Medicine, MedStar Good Samaritan Hospital, Baltimore, USA. 2. Internal Medicine, MedStar Union Memorial Hospital, Baltimore, USA

Corresponding author: Louay Aldabain, dabaeen@hotmail.com

Abstract
Coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2, primarily affects the respiratory system. While coronaviruses are not a common cause of neurological disease, they have been reported to cause direct central nervous system infection, as well as presumed para-infectious disorders. Here we report a very rare case of SARS-CoV-2 infection presenting as Miller Fisher syndrome with positive anti-GQ1b antibodies in a patient with a history of Guillain-Barré syndrome, which was treated with IV immunoglobulin resulting in marked improvement in her symptoms. Thus, a high index of suspicion and meticulous observation are the cornerstones to identifying possible uncommon presentations of COVID-19.

Categories: Internal Medicine, Neurology, Infectious Disease

Keywords: anti gq1b antibodies, ophthalmoplegia, ataxia, diplopia, miller fisher syndrome, covid-19

Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 19 (COVID-19), primarily infects the respiratory system and results in a spectrum of presentations ranging from being entirely asymptomatic to acute respiratory distress syndrome (ARDS) [1]. In addition, there has been growing evidence of non-respiratory complications related to COVID-19, including gastroenterological, hematological, nephrological, and neuropsychiatric symptoms [2]. While the pathophysiology explaining the former manifestations remains unclear, it is thought to be the result of an interplay between the virus and the host immune system [3].

Although it is not uncommon for COVID 19 to present with neurological manifestations, Miller Fisher syndrome (MFS), a rare variant of Guillain-Barré syndrome (GBS), secondary to COVID-19, has only been reported a handful of times in the literature [4-15]. Here we report a unique case of coronavirus disease 19 presenting as Miller Fisher syndrome with positive anti-GQ1b antibodies in a patient with a history of Guillain-Barré syndrome.

Case Presentation
A 39-year-old woman with a past medical history of hypertension, diabetes mellitus type 2, and GBS presented to the emergency department with diplopia, progressive bilateral upper and lower extremity weakness and numbness, and ataxia of two-week duration. She denied any recent infection or receiving any vaccinations. On physical examination, her blood pressure was 173/85 mmHg, and heart rate was 74 beats per minute. She was afebrile and saturating 100% on room air. She had left eye medial conjunctival erythema, deconjugate gaze, inability to abduct her left eye, inability to abduct her right eye with minimal adduction, elevation, and depression. She was unable to puff her cheeks bilaterally. Her strength was 4/5 in the proximal upper and lower extremities, length-dependent decrease in temperature sensation in the lower extremity starting from the knee bilaterally. Her deep tendon reflexes were +1 in triceps bilaterally, 0 in patella and ankles bilaterally, and a negative Babinski sign.

Pertinent laboratory tests at that time showed unremarkable complete blood count (CBC), complete metabolic panel (CMP), urine analysis (UA), thyroid-stimulating hormone (TSH), beta-human chorionic gonadotropin (BhCG), creatinine kinase (CK), serum protein electrophoresis (SPEP), human immunodeficiency virus 1/2 antibody/antigen (HIV AR/AG), syphilis screen, and vitamins B1, B6, and B12. Mid-turbinate COVID-19 direct real-time reverse transcription-polymerase complete reaction (RT-PCR) assay was positive. Table 1 shows antibody work-up.
**Antibody work-up**

| Antibody                                      | Result       |
|-----------------------------------------------|--------------|
| Sox 1 antibody IgG immunoblot.                | Negative     |
| CV 2.1 antibody IgG screen                   | Negative     |
| Purkinje/neuronal nuclear IgG screen          | Negative     |
| Neuronal antibody (amphiphysin)              | Negative     |
| Asialo-GM1B antibody IgG/IgM                 | Negative     |
| GM1 antibody IgG/IgM                         | Negative     |
| GM2 antibody IgG/IgM                         | Negative     |
| GD1a antibody IgG/IgM                        | Negative     |
| GD1B antibody IgG/IgM                        | Negative     |
| GQ1B antibody IgG/IgM                        | Negative     |
| IgG                                           | 397 mg/dL    |
| IgG                                           | 1488 mg/dL   |

**TABLE 1: Antibody work-up**

Magnetic resonance imaging (MRI) of the brain and spine with and without contrast, brain magnetic resonance angiography (MRA), and brain magnetic resonance venography (MRV) were all normal. A nerve conduction study showed electrophysiological evidence of a right median sensory neuropathy. Electromyography (EMG) showed evidence of reduced recruitment in the left tibialis anterior as well as the left vastus lateralis (Table 2). Cerebrospinal fluid (CSF) analysis, including cultures, oligoclonal bands, immunoglobulin G (IgG) index, cytology, and flow cytometry, were unremarkable, with no protein-albumin dissociation.

**TABLE 2: Electromyogram (EMG)**

EMG: Electromyogram, MUAP: motor unit action potential, IA: insertion activity, Fib: fibrillation, PSW: polyspike wave, Fasc: fasciculations, H.F: high frequency, Amp: amplitude, Dur: duration, PPP: polyphasic potentials, N: normal, L left, R: right, Tib: tibialis, Vast: Vastus, Abd: abductor, Poll: Pollicis

The patient was diagnosed with MFS in the setting of COVID-19 and was started on intravenous immunoglobulins (IVIG) at a dose of 20 g/day for five days, along with alternating patching of each eye. After treatment completion, she had subjective and objective improvement in her symptoms, and she was eventually discharged to an acute rehabilitation facility.

**Discussion**

MFS is an autoimmune disease characterized by a triad of ophthalmoplegia, ataxia, and areflexia. It is typically associated with high serum anti-GQ1b IgG in up to 83% of cases [16]. It accounts for 1-5% of cases of GBS in Western countries and is usually precipitated by preceding infections such as *Campylobacter jejuni*, and *Haemophilus influenzae* due to antigenic mimicry between peripheral nerves and the inciting microbe.
The case we describe is an unusual initial presentation of COVID-19 manifesting as MFS. The writers of this article did a Medline and PubMed Search and found that there are only twelve other cases of COVID-19-induced MFS [4-13]. We compared the findings in our study with the other studies for presentation, antibodies, MRI findings, and recurrence. Our case is the second case in the United States and the third case worldwide to report MFS as the initial presentation in a patient infected with COVID-19 [7,14]. All other cases reported COVID-19 symptoms preceding MFS presentation [4-6,8-13,15]. Including our case, only four cases of COVID-19-induced MFS reported positive anti-GQ1b antibodies [5,13,14]. The GQ1b ganglioside is a cell surface component concentrated in the paranodal regions of the extramedullary portion of CN III, IV, and VI. Antibodies against this ganglioside are thought to be the cause of ophthalmoplegia in MFS [19].

Brain MRI is not required for MFS diagnosis since findings are usually normal, and abnormalities are only detected in 2% of patients [20]. Three cases of COVID-19-induced MFS reported MRI findings which included prominent enhancement with gadolinium and T2 hyperintense signal of the cranial nerve III [6], enhancement, T2-hyperintensity, and enlargement of the left oculomotor nerve [4], and intrathecal cauda-equina enhancement [5].

Lastly, it is essential to note that among all the reported cases, only our patient had a remote history of GBS before presenting with MFS induced COVID 19. It is unclear if such a history increases the likelihood of MFS as a complication of COVID-19. Further studies are required to confirm the former.

Conclusions
We continue to learn more about the unexpected course the new virus might follow. Thus, a high index of suspicion and meticulous observation are the cornerstones to identifying possible uncommon presentations. Limited data is available in the literature on the association between Miller fisher syndrome and coronavirus disease 2019. Therefore, further research is required to enhance our understanding of the pathophysiology of such association. With that being said, we believe that this case provides a crucial addition to the collective knowledge about both the disease and its complications.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Kim GU, Kim MJ, Ra SH, Lee J, Bae S, Jung J, Kim SH: Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol Infect. 2020, 26:948. 10.1016/j.cmi.2020.04.040
2. AlSamman M, Caggiula A, Ganguli S, Misak M, Pourmand A: Non-respiratory presentations of COVID-19, a clinical review. Am J Emerg Med. 2020, 38:2444-54. 10.1016/j.ajem.2020.09.054
3. Parasher A: COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J. 2021, 97:312-20. 10.1136/postgradmedj-2020-138577
4. Dinkin M, Gao V, Kahn J, et al.: COVID-19 presenting with ophthalmoplegia from cranial nerve palsy. Neurology. 2020, 95:221-3. 10.1212/01.wnl.000000000009700
5. Lowery MM, Tafrar Malik M, Seemiller J, Tsai CS: Atypical variant of Guillain Barre syndrome in a patient with COVID-19. J Crit Care Med (Targu Mures). 2020, 6:231-6. 10.2478/jccm-2020-00058
6. Lantos JE, Strauss SB, Lin E: COVID-19-associated Miller Fisher syndrome: MRI findings. AJNR Am J Neuroradiol. 2020, 41:1184-6. 10.3174/ajnr.A6609
7. Ray A: Miller Fisher syndrome and COVID-19: is there a link? BMJ Case Rep. 2020, 15: 10.1136/bcr-2020-236419
8. Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, et al.: Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020, 95:e601-5. 10.1212/01.wnl.000000000009619
9. Fernández-Domínguez J, Ameijide-Sanluis E, García-Cabo C, García-Rodríguez R, Mateos V: Miller-Fisher-like syndrome related to SARS-CoV-2 infection (COVID 19). J Neurol. 2020, 267:2495-6. 10.1007/s00415-020-09912-2
10. Reyes-Bueno JA, García-Trujillo I, Urbanepa P, Ciano-Petersen NL, Postigo-Pozo MJ, Martinez-Tomás C, Serrano-Castro PI: Miller-Fisher syndrome after SARS-CoV-2 infection. Eur J Neurol. 2020, 27:1759-61. 10.1111/ene.145383
11. Senel M, Abu-Rumeilieh S, Michel D, Garibashvili T, Althaus K, Kasubek J, Otto M: Miller-Fisher syndrome after COVID-19: neurochemical markers as an early sign of nervous system involvement. Eur J Neurol. 2020, 27:2378-90. 10.1111/ene.14473
12. Manganotti P, Pesa Trento V, Buoite Stella A, et al.: Miller Fisher syndrome diagnosis and treatment in a
13. Biswas S, Ghosh R, Mandal A, et al.: COVID-19 Induced Miller Fisher syndrome presenting with autonomic dysfunction: a unique case report and review of literature. Neurohospitalist. 2022, 12:111-6. 10.1177/19418744211016709

14. Kopsik MR, Giouargas BK, Presley BC: A case report of acute motor and sensory polyneuropathy as the presenting symptom of SARS-CoV-2. Clin Pract Cases Emerg Med. 2020, 4:552-4. 10.5811/cpem.2020.6.48683

15. Kajani S, Kajani R, Huang CW, Tran T, Liu AK: Miller Fisher syndrome in the COVID-19 era - a novel target antigen calls for novel treatment. Cureus. 2021, 13:e12424. 10.7759/cureus.12424

16. Kaida K, Kanazaki M, Morita D, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S: Anti-ganglioside complex antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry. 2006, 77:1043-6. 10.1136/jnnp.2006.087940

17. Mori M, Kusahara S, Fukutake T, Yuki N, Hattori T: Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001, 56:1104-6. 10.1212/wnl.56.8.1104

18. Koga M, Gilbert M, Li J, et al.: Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology. 2005, 64:1605-11. 10.1212/01.WNL.0000160399.08456.7C

19. Chiba A, Kusunoki S, Ohara H, Machinami R, Kanazawa I: Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology. 1993, 43:1911-7. 10.1212/wnl.43.10.1911

20. Ito M, Kusahara S, Odaka M, Misawa S, Koga M, Hirata K, Yuki N: Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol. 2008, 255:674-82. 10.1007/s00415-008-0775-0